Swine flu will be high on the agenda of the ILSI-Biomed exhibition in Israel this June, as local and international companies developing universal flu vaccines and vaccine delivery methods exhibit their new products there. "It is crucial that Biomed Israel, as a leading life science conference, consistently feature issues having the greatest impact on the world," said Ruti Alon, ILSI Chairperson.

"We are fortunate that the top innovators in the area of flu vaccines and vaccine delivery platforms are participating in this year's event and we look forward to introducing their technologies to all the conference participants." Among the companies taking part in the event will be BiondVax Pharmaceuticals, which is developing a vaccination that will provide universal multi-season/multi-strain protection against human flu virus strains.

"Outbreaks of strains such as swine flu are exactly the reason why we are developing our vaccine. While vaccinations will cost, the global treatment of a pandemic would be a much more expensive proposition, especially given the global economic challenges we have today," said Dr. Ron Babecoff, founder, president and CEO of BiondVax. The three-day life sciences event will take place in Tel Aviv between June 15-17, and will feature executives from leading companies such as Bristol-Myers Squibb, Johnson & Johnson, Allergan, Avelere Health, Covidien, Astellas and many others

Source
Israel 21c